Singulair
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.
TABLE OF CONTENTS
4 Product Profiles
4 Singulair : Asthma
LIST OF FIGURES
8 Figure 1: Singulair for asthma – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Singulair in asthma
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Singulair in asthma
12 Figure 4: Singulair sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: Singulair drug profile
6 Table 2: Singulair pivotal trial data in asthma
13 Table 3: Singulair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
GE Healthcare’s New Value Proposition: The Strategic Language Of Software 
Sign up to the